No Impact of Corticosteroid Use During the Acute Phase on Persistent Symptoms Post-COVID-19

Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan Sui Ko, Adrien, Candellier, Alexandre, Mercier, Marie, Joseph, Cedric, Carette, Hortense, Basille, Damien, Lion-Daolio, Sylvie, Devaux, Stephanie, Schmit, Jean-Luc, Lanoix, Jean-Philippe, Andrejak, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394663/
https://www.ncbi.nlm.nih.gov/pubmed/36003084
http://dx.doi.org/10.2147/IJGM.S367273
Descripción
Sumario:Persistent COVID-19 symptoms may be related to residual inflammation, but no preventive treatment has been evaluated. This study aimed to analyze, in a prospective cohort, whether corticosteroid use in the acute phase of COVID-19 in hospitalized patients may reduce the risk of persistent COVID-19 symptoms. A total of 306 discharged patients, including 112 (36.6%) from the ICU, completed a structured face-to-face assessment 4 months after admission. Of these, 193 patients (63.1%) had at least one persistent symptom, mostly dyspnea (38.9%) and asthenia (37.6%). One-hundred and four patients have received corticosteroids. In multivariable adjusted regression analysis, corticosteroid use was not associated with the presence of at least one symptom (OR=1.00, 95% CI: 0.58–1.71, p=0.99) or with the number of persistent symptoms (p=0.74). Corticosteroid use remained ineffective when analyzing the ICU subpopulation separately. Our study suggests that corticosteroid use had no impact on persistent symptoms after COVID-19 in discharged patients.

Ejemplares similares